Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
September 30, 2016 – The FDA announced the discontinuation of Novartis’ Tyzeka (telbivudine) 600 mg tablets.
Download PDF
Return to publications
